Even if the Affordable Care Act is ultimately deemed unconstitutional, stakeholders wouldn’t allow the momentum surrounding value-based care models and biosimilars to stall, experts and provider groups said.
ACA repeal wouldn’t stop transition to value-based payment, efforts to lower drug spending
